Sana Biotechnology Inc.

2 months ago · prnewswire.com

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

2 months ago · globenewswire.com

SEATTLE, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at four investor conferences in September. The presentations will feature a business overview and update.

4 months ago · globenewswire.com

Peer-Reviewed Letter to the Editor Describes Updated Long-Term Findings Consistent with Initial Trial Data Featured in NEJM Article Published in 2025

8 months ago · globenewswire.com

Shared 12-month clinical results of ongoing UP421 type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression are safe and well-tolerated, evade detection by the immune system, and continue to function one year post-transplant

8 months ago · globenewswire.com

SEATTLE, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in March. The presentations will feature a business overview and update.

9 months ago · seekingalpha.com

Sana Biotechnology pivots to focus on its SC451 hypoimmune cell therapy for type 1 diabetes, aiming for a functional cure. Recent single-patient data validate SANA's immune-evasion technology, driving a sharp rally but underscoring early-stage risk and manufacturing challenges. With a $1B valuation and limited cash runway to YE26, SANA will likely require further dilution to fund pivotal clinical trials.

9 months ago · zacks.com

Does Sana Biotechnology (SANA) have what it takes to be a top stock pick for momentum investors? Let's find out.

9 months ago · zacks.com

The consensus price target hints at a 74.2% upside potential for Sana (SANA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

10 months ago · seekingalpha.com

SANA's thesis rests on hypoimmune islet replacement for T1D. UP421 gives it early human validation, and SC451 is the main scalable follow-on asset. SC451's planned 2026 IND is the primary catalyst going forward. In my view, this is their make-or-break catalyst this year. A favorable Phase 1 trial could rapidly re-rate the stock even higher, especially since it targets a sizeable TAM in TD1.

10 months ago · seekingalpha.com

Sana Biotechnology, Inc. (SANA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript